Fosamax Lawsuit 2026: Merck's $27.7M Jaw Settlement, the Revived Femur-Fracture Cases & Who Can File

Direct answer: Fosamax (alendronate) lawsuits accuse Merck of failing to warn that the osteoporosis drug could cause jaw-bone death and atypical femur fractures. Merck paid $27.7 million in 2013 to settle about 1,140 jaw-injury cases. Femur-fracture claims, dismissed in 2022, were revived by a federal appeals court in September 2024 — and lawyers are still reviewing cases in 2026.

Key facts:

  • 1995: Merck introduced Fosamax (alendronate sodium); before it went generic in 2008, the drug generated more than $3 billion in annual sales and was used by millions of Americans.
  • December 2013: Merck agreed to pay $27.7 million to settle roughly 1,140 lawsuits alleging jaw-bone deterioration (osteonecrosis of the jaw), requiring 100 percent claimant participation; the deal did not cover about 4,115 pending femur-fracture claims.
  • October 2010: the FDA required label warnings about atypical femur fractures, and later suggested users consider limiting bisphosphonate therapy to a three-to-five-year period.
  • March 2022: a federal judge dismissed roughly 500 femur-fracture lawsuits on preemption grounds; September 2024: the Third Circuit Court of Appeals revived them, finding Merck had not shown the FDA would have rejected any state-required warning.
  • 2019: the U.S. Supreme Court ruled that federal law can preempt state failure-to-warn claims when the FDA governs the label — the legal doctrine at the center of this litigation.

What Fosamax Is — and Why Millions Took It

A bisphosphonate is a class of drug that slows the breakdown of bone, allowing density to rebuild. Osteoporosis is the progressive thinning of bone that makes fractures — especially of the hip, spine, and wrist — far more likely, above all in postmenopausal women. Fosamax became the flagship treatment: convenient, widely prescribed, and for years considered the responsible way to protect aging bones.

The paradox that drives this litigation is brutal in its simplicity. The drug meant to make bones stronger was, according to thousands of plaintiffs, making some bones brittle in a new and specific way — or killing portions of the jaw outright. Those fractures often arrived without any meaningful trauma: a step off a curb, a twist while standing, a stumble from standing height or less.

The Two Injuries at the Center of the Lawsuits

Osteonecrosis of the jaw (ONJ) literally means "bone death of the jaw" — exposed, deteriorating jawbone, usually after dental work, that fails to heal and becomes intensely painful. It was the first injury to reach the courts in large numbers, and the first to settle.

An atypical femur fracture is a break in the thigh bone that occurs with little or no trauma, often starting as a dull ache in the thigh or groin weeks before the bone gives way. These fractures look different from ordinary breaks on X-rays — they tend to occur just below the hip in the subtrochanteric region, and they can happen on both sides. Plaintiffs argue the drug's suppression of bone remodeling left bones dense-looking but fragile, like an old chalk stick.

The $27.7 Million Jaw-Injury Settlement

In December 2013, Merck confirmed it would pay $27.7 million to settle roughly 1,140 lawsuits filed by former Fosamax users who developed osteonecrosis of the jaw. The deal required 100 percent participation from eligible claimants and proof that each satisfied eligibility criteria — a structure designed to buy total peace on the jaw-injury claims.

What the settlement did not cover is just as important: at the time, Merck continued to face about 4,115 lawsuits from people alleging femur fractures or other bone injuries from Fosamax. The jaw chapter closed; the fracture chapter was about to become a decade-long legal war.

The Femur-Fracture Cases: Dismissed, Then Revived

Starting in 2008, hundreds of Fosamax patients sued Merck over atypical fractures, arguing the company knew its osteoporosis drug could break thigh bones and chose not to warn. The cases were consolidated in federal court. Merck's defense leaned on preemption — the doctrine that federal law, through FDA control of drug labels, can block state-law claims. Merck pointed to a 2009 letter in which the FDA rejected its proposed label change as evidence no warning could have been added.

The defense worked twice: a judge dismissed the fracture claims, the U.S. Supreme Court's 2019 ruling on preemption sent the question back down, and in March 2022 a district judge dismissed the roughly 500 consolidated cases again. Then, in September 2024, the Third Circuit Court of Appeals overturned the dismissal, ruling that Merck had not shown the FDA would have rejected any and all warnings state law might have required. The cases — dormant for years — are alive again.

What the FDA Said: The 2010 Warning and the 3-to-5-Year Guidance

The FDA did not stay silent. In October 2010, the agency required warnings about atypical femur fractures on the labels of Fosamax and other oral bisphosphonates such as Actonel and Boniva. Later, the agency suggested that users consider limiting therapy to a three-to-five-year period, which might preserve the drugs' osteoporosis benefits while reducing long-term risks.

That guidance matters for two reasons. Medically, it reflects the core allegation: long-term suppression of bone turnover carries costs that short-term use does not. Legally, the timeline of what Merck knew, when it sought label changes, and what the FDA allowed is precisely the record the revived cases will now litigate.

Who Can Still File a Fosamax Lawsuit in 2026

The statute of limitations — the filing deadline — varies by state and usually runs from when you knew or should have known the drug caused your injury. Because the fracture cases were dismissed and then revived, and because many patients only recently connected a years-old fracture to Fosamax, attorneys continue to evaluate new claims rather than declaring the door closed.

Compensation varies widely by case; most settlements are confidential, so treat any public "average payout" figure with skepticism. The documented public figures are the $27.7 million jaw settlement and the court rulings themselves — not a promise of what any individual claim is worth. If you took Fosamax long-term and suffered a jaw injury or a low-trauma thigh fracture, a mass-tort attorney can check your state's deadline and whether your records fit the litigation's criteria.

How a Fosamax Case Is Built

A strong file starts with two paper trails: pharmacy records proving long-term Fosamax use, and medical records documenting the injury — dental records for ONJ, radiology for the fracture. Lawyers look for the pattern courts recognize: years of use, a fracture with minimal trauma, and no other clear explanation.

Most firms take these cases on a contingency fee, meaning no upfront payment and the fee comes from any recovery. Be ready for patience: with cases revived in 2024 and the preemption fight still unresolved, timelines stretch. But the infrastructure of the litigation — the consolidated dockets, the expert records, the settlement history — means your case would not be starting from zero.

For more explainers on complex drug and device cases, see the Problem Solved channel. Related coverage: the Xeljanz lawsuit, the talc powder litigation, and the Suboxone tooth-decay lawsuits.

Who Benefits From This — and Who Does Not

A Fosamax file turns on two paper trails — proof of long-term use and medical proof of the injury — and on timing, because filing deadlines usually run from when you discovered the connection, and the femur-fracture cases were revived only in September 2024.

Who benefits:

  • Long-term Fosamax users who developed osteonecrosis of the jaw, often after dental work: Dental records plus pharmacy records connect the drug to the jaw injury at the center of the $27.7 million settlement covering roughly 1,140 cases.
  • Patients with an atypical femur fracture after little or no trauma: Radiology showing a break just below the hip, sometimes preceded by a dull thigh or groin ache lasting weeks, matches the pattern the revived fracture cases allege.
  • People who kept years of pharmacy and treatment records: Pharmacy proof of long-term use together with dental or radiology documentation is exactly the file the article says lawyers look for first.

Who benefits little or not at all:

  • People with an ordinary fragility fracture: Typical osteoporosis fractures look different from atypical femur fractures and do not fit the pattern these cases allege.
  • Anyone expecting a published average payout: Most settlements are confidential, so no average can be promised from public figures; the documented public figure is the $27.7 million jaw settlement.
  • People with a diagnosis alone and no proof of long-term use: Without pharmacy records showing long-term Fosamax use, connecting the injury to the drug is difficult to establish.

Related reading: DePuy Hip Implant Lawsuit 2026: The $2.5B ASR Settlement, the $1B Pinnacle Verdict & Who Can Still File.

Frequently Asked Questions

Is it too late to sue over Fosamax?

Not necessarily. Deadlines vary by state and often run from when you discovered the connection, and the femur-fracture cases were revived by a federal appeals court in September 2024 — attorneys are still reviewing new claims in 2026.

What are the symptoms of an atypical femur fracture?

A dull, unexplained ache in the thigh or groin lasting weeks, sometimes in both legs, followed by a break from minimal trauma such as stepping off a curb. Imaging typically shows the fracture just below the hip.

How much was the Fosamax jaw settlement?

Merck agreed in December 2013 to pay $27.7 million to settle roughly 1,140 lawsuits alleging osteonecrosis of the jaw, with 100 percent claimant participation required. It did not cover the pending femur-fracture claims.

Did the FDA warn about Fosamax fractures?

Yes. In October 2010 the FDA required label warnings about atypical femur fractures for Fosamax and similar bisphosphonates, and later suggested limiting therapy to three to five years.

Who benefits from a Fosamax claim — and who does not?

Long-term users with documented jaw-bone death after dental work or an atypical femur fracture after minimal trauma benefit most, especially when pharmacy records prove long-term use and dental or radiology records document the injury. Ordinary fragility fractures do not fit the alleged pattern, a diagnosis without use records is weak, and no average payout can be promised because most settlements are confidential.

How do I start a Fosamax claim?

Gather two paper trails first: pharmacy records proving long-term Fosamax use, and medical records documenting the injury — dental records for jaw problems, radiology for a femur fracture. Note when you first discovered the connection, since state deadlines usually run from discovery, and consult an attorney promptly; most firms work on a contingency fee with no upfront payment. Discuss any health questions with your physician.

This article is general information, not legal or medical advice. If you believe a medication injured you, consult a qualified attorney in your state and a physician about your health.

Watch on YouTube

Problem Solved on YouTube